Loading...
Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK plus non-small cell lung cancer (NSCLC): ALTA-1L final results
Tiseo, M. Popat, S. Kim, H. R. Ahn, M. J. Yang, J. C. Han, J. Y. Hochmair, M. J. Lee, K. H. Delmonte, A. Campelo, M. R. G.
Tiseo, M.
Popat, S.
Kim, H. R.
Ahn, M. J.
Yang, J. C.
Han, J. Y.
Hochmair, M. J.
Lee, K. H.
Delmonte, A.
Campelo, M. R. G.
Citations
Altmetric:
Abstract
Affiliation
Description
Date
2022
Publisher
Collections
Files
Keywords
Type
Meetings and Proceedings
Citation
Tiseo M, Popat S, Kim HR, Ahn M-J, Yang JC, Han J-Y, et al. 29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results. Vol. 33, Annals of Oncology. Elsevier BV; 2022. p. S44–5.